Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

Abstract:

BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions to rituximab is high. Reactions to monoclonal antibodies, including rituximab, vary widely in type and severity, but may include mild pruritis and rash to more severe complications such as Stevens-Johnson syndrome and anaphylactic reactions. OBJECTIVE:To assess the incidence of infusion-associated reactions in our MS patients receiving rituximab infusions and compare it to previous trials investigating rituximab for treating MS. METHODS:From 1 to 30 November 2009, we retrospectively reviewed medical charts from Partners Multiple Sclerosis Centre, Brookline, MA, USA, of patients being treated with rituximab for MS between 20 November 2007 and 24 November 2009 for evidence of infusion-associated reactions and further classified reactions on a grading scale. RESULTS:During the period studied, 70 patients were infused with rituximab. Infusion-associated events occurred in 25.7% of our patients. Reactions were mild to moderate and most commonly occurred during the first infusion. Most patients were able to complete the infusion after appropriate treatment of the reaction was administered, and most patients went on to receive subsequent doses without any further reactions. CONCLUSIONS:The occurrence of infusion-associated reactions to rituximab in patients with MS is fairly common. However, premedication that includes corticosteroids may reduce the incidence of reactions dramatically. Should they occur, proper treatment of reactions with histamine H(1) or H(2) receptor antagonists and infusion rate reduction is an effective management strategy in this situation.

journal_name

Drug Saf

journal_title

Drug safety

authors

Brown BA,Torabi M

doi

10.2165/11585960-000000000-00000

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

117-23

issue

2

eissn

0114-5916

issn

1179-1942

pii

3

journal_volume

34

pub_type

杂志文章
  • Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports.

    abstract:INTRODUCTION:As asthma medications are frequently prescribed for children, knowledge of the safety of these drugs in the paediatric population is important. Although spontaneous reports cannot be used to prove causality of adverse events, they are important in the detection of safety signals. OBJECTIVE:Our objective w...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00870-x

    authors: Baan EJ,de Smet VA,Hoeve CE,Pacurariu AC,Sturkenboom MCJM,de Jongste JC,Janssens HM,Verhamme KMC

    更新日期:2020-01-01 00:00:00

  • Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.

    abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00831-4

    authors: Ménard T,Barmaz Y,Koneswarakantha B,Bowling R,Popko L

    更新日期:2019-09-01 00:00:00

  • Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

    abstract::Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-020-00926-3

    authors: Jackson DJ,Korn S,Mathur SK,Barker P,Meka VG,Martin UJ,Zangrilli JG

    更新日期:2020-05-01 00:00:00

  • Improving safety reporting from randomised trials.

    abstract::Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225020-00002

    authors: Ioannidis JP,Lau J

    更新日期:2002-01-01 00:00:00

  • Safety issues in the use of methylphenidate. An American perspective.

    abstract::Methylphenidate is the most widely use psychotropic medication in children in the US. It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects. However, the abuse of methylphenidate for the purpose of experiencing a 'high...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199717030-00001

    authors: Rappley MD

    更新日期:1997-09-01 00:00:00

  • Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.

    abstract::In the original publication of the article, the trend line for non-EEA cases in figure 4 is incorrect. In this correction, the original Fig. 4 (Fig. 1) and the correct Fig. 4 (Fig. 2) are published. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0700-0

    authors: Newbould V,Le Meur S,Goedecke T,Kurz X

    更新日期:2018-12-01 00:00:00

  • Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

    abstract::Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of bisphosphonates currentl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629120-00005

    authors: Bobba RS,Beattie K,Parkinson B,Kumbhare D,Adachi JD

    更新日期:2006-01-01 00:00:00

  • Poisoning by thallium. A study of five cases.

    abstract::Thallium poisoning seldom occurs in Spain. This article reports 5 cases of thallium poisoning, of which 4 of the patients belonged to the same family. The cases occurred in or near Granada between 1985 and 1987. The symptoms were initially gastrointestinal (vomiting, abdominal pain, gastrointestinal haemorrhage, etc.)...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199005050-00006

    authors: Villanueva E,Hernandez-Cueto C,Lachica E,Rodrigo MD,Ramos V

    更新日期:1990-09-01 00:00:00

  • Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.

    abstract:INTRODUCTION:Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. OBJECTIVE:Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the cardiovascular effects of once-daily valbenazine in patients with a psyc...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0623-1

    authors: Thai-Cuarto D,O'Brien CF,Jimenez R,Liang GS,Burke J

    更新日期:2018-04-01 00:00:00

  • Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis.

    abstract:INTRODUCTION AND OBJECTIVE:The therapeutic role of fecal microbiota transplantation in ulcerative colitis varies across different reports. This study aims to evaluate the long-term safety and efficacy of a strategy called step-up fecal microbiota transplantation for ulcerative colitis. METHODS:Two clinical trials (NCT...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00809-2

    authors: Ding X,Li Q,Li P,Zhang T,Cui B,Ji G,Lu X,Zhang F

    更新日期:2019-07-01 00:00:00

  • Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?

    abstract::Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the contribution of specific ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528120-00002

    authors: Nolan D

    更新日期:2005-01-01 00:00:00

  • Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

    abstract:BACKGROUND:Drug-drug interactions (DDIs) are a well known risk factor for adverse drug reactions. HMG-CoA reductase inhibitors ('statins') are a cornerstone in the treatment of dyslipidaemia and patients with dyslipidaemia are concomitantly treated with a variety of additional drugs. Since DDIs are associated with adve...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528030-00007

    authors: Rätz Bravo AE,Tchambaz L,Krähenbühl-Melcher A,Hess L,Schlienger RG,Krähenbühl S

    更新日期:2005-01-01 00:00:00

  • Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

    abstract::Regular treatment with both long- and short-acting beta 2-agonists results in tolerance to their bronchoprotective effects, although the relevance of this phenomenon in terms of long term asthma control remains unclear. However, there appears to be no appreciable difference between the 2 long-active beta 2-agonists, s...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199716050-00002

    authors: Lipworth BJ

    更新日期:1997-05-01 00:00:00

  • Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.

    abstract:BACKGROUND:In the UK, spontaneous reporting of suspected adverse drug reactions (ADRs) by healthcare professionals has been in operation since 1964 through the Yellow Card Scheme (YCS). From 2005, patients themselves have been able to submit Yellow Card reports. OBJECTIVE:To compare patient characteristics, suspected ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11536510-000000000-00000

    authors: McLernon DJ,Bond CM,Hannaford PC,Watson MC,Lee AJ,Hazell L,Avery A,Yellow Card Collaboration.

    更新日期:2010-09-01 00:00:00

  • Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

    abstract:BACKGROUND:Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE:The aim of the study was to characterize ADRs reported to the WHO-ADR database, ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03262002

    authors: Aagaard L,Strandell J,Melskens L,Petersen PS,Holme Hansen E

    更新日期:2012-12-01 00:00:00

  • Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.

    abstract:BACKGROUND:Clozapine is an antipsychotic medication associated with a lower suicide rate compared with other antipsychotic agents. Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis. OB...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730010-00005

    authors: Haas SJ,Hill R,Krum H,Liew D,Tonkin A,Demos L,Stephan K,McNeil J

    更新日期:2007-01-01 00:00:00

  • Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case-Control Study in Men of Subfertile Couples from the Netherlands.

    abstract:INTRODUCTION:Gastric acid-related symptoms are highly prevalent in the general population (21-40%), and more than 11% of individuals use medication for the treatment of these symptoms. The uptake of micronutrients is dependent on the gastrointestinal potential of hydrogen (pH). OBJECTIVE:We hypothesized that medicatio...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0488-8

    authors: Huijgen NA,Goijen HJ,Twigt JM,Mulders AG,Lindemans J,Dohle GR,Laven JS,Steegers-Theunissen RP

    更新日期:2017-03-01 00:00:00

  • Current challenges and controversies in drug-induced liver injury.

    abstract::Current key challenges and controversies encountered in the identification of potentially hepatotoxic drugs and the assessment of drug-induced liver injury (DILI) are covered in this article. There is substantial debate over the classification of DILI itself, including the definition and validity of terms such as 'int...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261997

    authors: Corsini A,Ganey P,Ju C,Kaplowitz N,Pessayre D,Roth R,Watkins PB,Albassam M,Liu B,Stancic S,Suter L,Bortolini M

    更新日期:2012-12-01 00:00:00

  • Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.

    abstract:BACKGROUND:Screening large databases of spontaneous case reports of possible adverse drug reactions (ADRs) is an established method of identifying hitherto unknown adverse effects of medicinal products; however, there is a lack of consensus concerning the value of formal statistical screening procedures in guiding such...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11534410-000000000-00000

    authors: Alvarez Y,Hidalgo A,Maignen F,Slattery J

    更新日期:2010-06-01 00:00:00

  • Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management.

    abstract:BACKGROUND:Problematic prescription drug use is reflected by or associated with drug-seeking aberrant behaviours. Research gaps include lack of post-marketing evidence and instruments. As part of the pharmacovigilance requirements, a risk management plan was developed for fentanyl buccal tablets (FEBT) by the manufactu...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0193-4

    authors: Layton D,Osborne V,Al-Shukri M,Shakir SA

    更新日期:2014-08-01 00:00:00

  • Pharmacists' interventions in prescribing errors at hospital discharge: an observational study in the context of an electronic prescribing system in a UK teaching hospital.

    abstract:BACKGROUND:Pharmacists have an essential role in improving drug usage and preventing prescribing errors (PEs). PEs at the interface of care are common, sometimes leading to adverse drug events (ADEs). This was the first study to investigate, using a computerized search method, the number, types, severity, pharmacists' ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11538310-000000000-00000

    authors: Abdel-Qader DH,Harper L,Cantrill JA,Tully MP

    更新日期:2010-11-01 00:00:00

  • Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

    abstract:BACKGROUND:Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited. OBJECTIVE:To retrospectively assess the safety profile of interferon-beta-1a therapy with respect to liver function durin...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-200326110-00006

    authors: Francis GS,Grumser Y,Alteri E,Micaleff A,O'Brien F,Alsop J,Stam Moraga M,Kaplowitz N

    更新日期:2003-01-01 00:00:00

  • Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

    abstract::The term 'benefit-risk ratio' is often used as a general term linked to the use of a medicine. To balance risk and benefit is, however, a very complex exercise. For most medicines the benefits are limited to a few indications and for an individual patient there is usually only a single benefit sought but the potential...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199615010-00001

    authors: Edwards R,Wiholm BE,Martinez C

    更新日期:1996-07-01 00:00:00

  • Detection of adverse drug events and other treatment outcomes using an electronic prescribing system.

    abstract:BACKGROUND:Current pharmacosurveillance methods do not provide timely information on drug safety and effectiveness. Real-time surveillance using electronic prescribing systems could address this problem; however, the data collected using these systems has not been validated. We investigated the accuracy of using orders...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831110-00005

    authors: Eguale T,Tamblyn R,Winslade N,Buckeridge D

    更新日期:2008-01-01 00:00:00

  • PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.

    abstract:INTRODUCTION:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were associated with a risk of neurocognitive adverse drug reactions (ADRs). OBJECTIVE:We aimed to investigate the occurrence of neuropsychiatric ADRs related to PCSK9Is. METHODS:We analyzed Individual Case Safety Reports (ICSRs) sent thr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-01021-3

    authors: di Mauro G,Zinzi A,Scavone C,Mascolo A,Gaio M,Sportiello L,Ferrajolo C,Rafaniello C,Rossi F,Capuano A

    更新日期:2020-12-22 00:00:00

  • What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.

    abstract::Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-0681-z

    authors: van Eekeren R,Rolfes L,Koster AS,Magro L,Parthasarathi G,Al Ramimmy H,Schutte T,Tanaka D,van Puijenbroek E,Härmark L

    更新日期:2018-11-01 00:00:00

  • Tolerabilities of antiretrovirals in paediatric HIV infection.

    abstract::Data on the efficacy and tolerability of antiretrovirals in children are limited as, in contrast to adult studies, large paediatric cohort studies are lacking. Thus, data pertaining to adults are often extrapolated to children despite the acknowledgement that children are not little adults. This review summarises info...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225140-00001

    authors: Lemberg DA,Palasanthiran P,Goode M,Ziegler JB

    更新日期:2002-01-01 00:00:00

  • beta-blockers. Drug interactions of clinical significance.

    abstract::The clinician prescribing beta-blockers for his or her patients is faced with an often difficult situation. There are many beta-blockers, each with its own pharmacological profile. Patients are often taking multiple medications, thus increasing the risk of both anticipated and unexpected drug interactions. Reports of ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199513060-00005

    authors: Blaufarb I,Pfeifer TM,Frishman WH

    更新日期:1995-12-01 00:00:00

  • Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

    abstract::Although the aetiology of inflammatory bowel disease remains elusive, many agents are available for the control of symptoms and inflammation. Knowledge of drug pharmacology, indications and side effects is essential to ensure the best possible clinical care while minimising toxicity and inappropriate use. Sulfasalazin...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106030-00005

    authors: Hanauer SB,Stathopoulos G

    更新日期:1991-05-01 00:00:00

  • Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

    abstract:INTRODUCTION:The use of mobile apps is increasing in medicine. In pharmacovigilance, mobile apps may help to increase adverse drug reaction reporting and improve the communication of safety issues. The Toulouse University Pharmacovigilance Center has developed VigiBIP®, a free smartphone app available on Android and Ap...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0630-2

    authors: Montastruc F,Bagheri H,Lacroix I,Damase-Michel C,Chebane L,Rousseau V,Jouanjus E,Lapeyre-Mestre M,Durrieu G,Montastruc JL

    更新日期:2018-05-01 00:00:00